The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.

30 August 2024 (16:05 - 16:15)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Maciej Banach

Medical University of Lodz, Lodz (Poland)

5 More presentations in this session

Presentation thumbnail

Comparative efficacy of colchicine and intensive LDL-C lowering in patients with ASCVD receiving statins: a network meta-analysis of randomised controlled trials

Doctor Z. Ou (Chongqing, CN)

Abstract Slides Video

Presentation thumbnail

Deciphering lipoprotein(a) atherogenicity with use of high-throughput proteomics

Doctor J. Morze (Gothenburg, SE)

Abstract Slides Video

Presentation thumbnail

Contemporary LDL-cholesterol management in male and female patients at high-cardiovascular risk: results from the European observational SANTORINI study

Professor D. Nanchen (Lausanne, CH)

Abstract Slides Video

Presentation thumbnail

The change of paradigm: high HDL-c levels could not mean a long lifespan

Doctor F. Sousa (Funchal, PT)

Abstract Slides Video

Presentation thumbnail

Interleukin-6 signalling, lipoprotein (a) lowering and cardiovascular disease: a mendelian randomisation study

Doctor S. Brennan (Dublin, IE)

Abstract Slides Video

Access the full session

Session thumbnail

Dyslipidaemia: novel diagnostics and therapy options

The Event

Event poster

ESC Congress 2024

30 August 2024 16:05 CET

You may be interested in

Congress Presentation

Oral LDL-c lowering therapies - the basis of prevention

Congress Session

Advancing lipid management: insights from real-world evidence and combination therapy trials

Congress Presentation

Possible shifts in paradigms for lipid-lowering therapies in acute coronary syndrome patients: combination therapy from Day 1

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources